Octapharma AG - Press Release & Archive 
EN: Navigation mit Access Keys
- [Alt + 0] - Startseite
- [Alt + 1] - Navigation
- [Alt + 2] - Inhalt
- [Alt + 3] - Kontakt
- [Alt + 4] - Sitemap
- [Alt + 5] - Suche
EN: Hauptnavigation
Press Release & Archive
News
New therapeutic option for immunocompromised patients in Canada
05.04.2013
Toronto, Canada April 4th, 2013: Octapharma Canada is pleased to announce that starting April 2013, Canadian physicians and patients will now have access to Intravenous Human Immune Globulin (IVIG) Octagam®10%. While new to...
Octapharma Group release 2012 Annual Report
25.03.2013
An impressive return of octagam® 5% and 10% consolidated the financial performance and financial position of the Octapharma Group in the year 2012. Significant increases in net sales combined with a good performance in the...
Octapharma clinical study assessing the efficacy and tolerability of intravenous immunoglobulin (IVIG, Octagam 10%) in patients with Alzheimer’s disease
05.02.2013
On January 31, 2013, Lancet Neurology published online the largest completed clinical study to date assessing the efficacy and tolerability of intravenous immunoglobulin (IVIG, Octagam 10%) in patients with Alzheimer’s...
FDA Approves Octaplas® Expanding Octapharma U.S. Transfusion Medicine Therapies
22.01.2013
HOBOKEN, N.J. January 22, 2013 – Octapharma USA today announced that the U.S. Food and Drug Administration (FDA) has approved Octaplas®, its solvent/detergent treated pooled human plasma. Octaplas® is indicated for the management...